- Myriad Genetics' (MYGN, Financial) GeneSight test shows a 39% reduction in psychiatric hospitalizations for depression patients.
- The study published in the Journal of Clinical Psychopharmacology highlights improved medication management through the GeneSight test.
- Results suggest significant cost savings for healthcare systems due to fewer hospitalizations and optimized prescribing practices.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced positive findings from a study published in the Journal of Clinical Psychopharmacology. This study showcased the effectiveness of the GeneSight® Psychotropic Test in reducing psychiatric hospitalizations among patients with major depressive disorder.
According to the study, there was a 39% relative reduction in psychiatric-related hospitalizations for patients who underwent GeneSight testing. Furthermore, those switched to medications with minimal gene-drug interactions experienced a remarkable 44% decrease in psychiatric hospitalizations. This underscores the GeneSight test's pivotal role in personalized medication management, enabling healthcare providers to make informed prescribing decisions.
The findings also highlighted a 40% reduction in prescriptions involving significant gene-drug interactions, indicating a shift toward more precise psychiatric care. This advancement in treatment strategies is expected to alleviate the traditional trial-and-error approach in medication selection, ultimately improving patient outcomes and healthcare resource utilization.
Through these significant reductions in hospitalizations and enhanced prescription practices, the GeneSight test from Myriad Genetics demonstrates its potential to lower healthcare costs and support the broader adoption of precision medicine in psychiatric care. The study suggests that incorporating genetic insights into the treatment process can meaningfully impact patient management and stabilization, offering a promising outlook for stakeholders in the healthcare ecosystem.
